BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26385822)

  • 1. Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients.
    De Rose F; Cozzi L; Navarria P; Ascolese AM; Clerici E; Infante M; Alloisio M; Testori A; Toschi L; Finocchiaro G; Santoro A; Scorsetti M
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):13-20. PubMed ID: 26385822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
    Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
    Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments.
    Navarria P; Ascolese AM; Tomatis S; Cozzi L; De Rose F; Mancosu P; Alongi F; Clerici E; Lobefalo F; Tozzi A; Reggiori G; Fogliata A; Scorsetti M
    Radiat Oncol; 2014 Apr; 9(1):91. PubMed ID: 24694067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.
    Li Q; Swanick CW; Allen PK; Gomez DR; Welsh JW; Liao Z; Balter PA; Chang JY
    Radiother Oncol; 2014 Aug; 112(2):256-61. PubMed ID: 25108807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy for central lung tumors.
    Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
    J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.
    Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
    J Thorac Oncol; 2011 Dec; 6(12):2036-43. PubMed ID: 21892102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer.
    Bongers EM; Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
    J Thorac Oncol; 2011 Dec; 6(12):2052-7. PubMed ID: 22052227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies.
    Mesko S; Sandler K; Cohen J; Konecny G; Steinberg M; Kamrava M
    Int J Gynecol Cancer; 2017 Feb; 27(2):403-408. PubMed ID: 27870704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
    Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
    Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
    Chang JY; Li QQ; Xu QY; Allen PK; Rebueno N; Gomez DR; Balter P; Komaki R; Mehran R; Swisher SG; Roth JA
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1120-8. PubMed ID: 24661665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases.
    Boda-Heggemann J; Frauenfeld A; Weiss C; Simeonova A; Neumaier C; Siebenlist K; Attenberger U; Heußel CP; Schneider F; Wenz F; Lohr F
    Radiat Oncol; 2014 Jan; 9():10. PubMed ID: 24401323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
    Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
    Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort.
    Murray L; Ramasamy S; Lilley J; Snee M; Clarke K; Musunuru HB; Needham A; Turner R; Sangha V; Flatley M; Franks K
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):4-12. PubMed ID: 26474546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study.
    Ferrero C; Badellino S; Filippi AR; Focaraccio L; Giaj Levra M; Levis M; Moretto F; Torchio R; Ricardi U; Novello S
    Lung Cancer; 2015 Sep; 89(3):350-6. PubMed ID: 26164208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
    Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P
    BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
    Bilal H; Mahmood S; Rajashanker B; Shah R
    Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.